Vaxart, Inc. creates oral vaccines using its own proprietary platform, with a focus on recombinant protein vaccines. The company's product pipeline includes vaccines for norovirus, seasonal influenza, respiratory syncytial virus, and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus, and is headquartered in South San Francisco, California.